Rozenman Mary M. Form 4 December 28, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

if no longer subject to Section 16. Form 4 or

Check this box

Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

\$0.0001

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Rozenman Mary M. Issuer Symbol Aimmune Therapeutics, Inc. [AIMT] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner X_ Officer (give title Other (specify AIMMUNE THERAPEUTICS. 12/26/2017 below) below) INC., 8000 MARINA See Remarks **BOULEVARD, SUITE 300** (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting BRISBANE, CA 94005-1884 Person

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 5. Amount of 1. Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) 6. 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction Disposed of (D) Securities Ownership Indirect (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial (Month/Day/Year) Owned Direct (D) Ownership (Instr. 8) **Following** or Indirect (Instr. 4) Reported (I) (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) Code V Amount (D) Price Common Stock, 12/26/2017 75,010 \$ 3.022 D M Α 75,139 \$0.0001 par value Common \$ Stock, $S^{(1)}$ 12/26/2017 11.000 38.8263 D D 64,139 \$0.0001 (2) par value $S^{(1)}$ Common 12/26/2017 1,500 D \$ 39.252 62,639 D (3) Stock.

par value							
Common Stock, \$0.0001 par value	12/26/2017	S(1)	10,700	D	\$ 38.8151 (2)	51,939	D
Common Stock, \$0.0001 par value	12/26/2017	S <u>(1)</u>	1,800	D	\$ 39.225 (4)	50,139	D
Common Stock, \$0.0001 par value	12/26/2017	S <u>(1)</u>	11,000	D	\$ 38.8286 (5)	39,139	D
Common Stock, \$0.0001 par value	12/26/2017	S <u>(1)</u>	1,500	D	\$ 39.25 (<u>6)</u>	37,639	D
Common Stock, \$0.0001 par value	12/26/2017	S <u>(1)</u>	11,000	D	\$ 38.8221	26,639	D
Common Stock, \$0.0001 par value	12/26/2017	S(1)	1,500	D	\$ 39.2313 (8)	25,139	D
Common Stock, \$0.0001 par value	12/26/2017	S <u>(1)</u>	4,310	D	\$ 38.8026 <u>(9)</u>	20,829	D
Common Stock, \$0.0001 par value	12/26/2017	S <u>(1)</u>	700	D	\$ 39.2557 (10)	20,129	D
Common Stock, \$0.0001 par value	12/26/2017	S(1)	8,800	D	\$ 38.8253 (11)	11,329	D
Common Stock, \$0.0001 par value	12/26/2017	S(1)	1,200	D	\$ 39.2783 (12)	10,129	D
Common Stock, \$0.0001 par value	12/26/2017	S(1)	6,400	D	\$ 38.7263 (13)	3,729	D

Edgar Filing: Rozenman Mary M. - Form 4

Common \$\$ Stock, \$0.0001 par value \$\$ $S_{\underline{(1)}} = 3,600 \text{ D} = 39.1526 \text{ 129} \text{ D}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	iorDerivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		3 (
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 3.022	12/26/2017		M	,	75,010	<u>(15)</u>	04/17/2025	Common Stock	75,010	

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Rozenman Mary M.

AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300

See Remarks

Date

BRISBANE, CA 94005-1884

Signatures

/s/ Douglas T. Sheehy, as Attorney-in-Fact for Mary M.
Rozenman 12/28/2017

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 3

Edgar Filing: Rozenman Mary M. - Form 4

- (1) The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- The transaction was executed in multiple trades in prices ranging from \$38.13 to \$39.13, inclusive. The price reported in Column 4

 (2) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$39.14 to \$39.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$39.14 to \$39.32, inclusive. The price reported in Column 4

 (4) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$38.14 to \$39.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$39.15 to \$39.35, inclusive. The price reported in Column 4

 (6) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$38.12 to \$39.12, inclusive. The price reported in Column 4
 (7) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$39.13 to \$39.32, inclusive. The price reported in Column 4

 (8) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$38.14 to \$39.12, inclusive. The price reported in Column 4

 (9) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$39.15 to \$39.32, inclusive. The price reported in Column 4 (10) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$38.15 to \$39.14, inclusive. The price reported in Column 4 (11) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$39.16 to \$39.54, inclusive. The price reported in Column 4 (12) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$38.06 to \$39.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$39.07 to \$39.32, inclusive. The price reported in Column 4

 (14) above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
 - The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from February 1, 2015 (the "Vesting Commencement Date")
- (15) and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

Senior VP, Corporate Development and Strategy

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.